Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.

Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ.

Cancer Res. 2012 Jan 1;72(1):239-48. doi: 10.1158/0008-5472.CAN-11-2263. Epub 2011 Nov 22.

2.

Transient decrease in tumor oxygenation after intravenous administration of pyruvate.

Saito K, Matsumoto S, Devasahayam N, Subramanian S, Munasinghe JP, Morris HD, Lizak MJ, Ardenkjaer-Larsen JH, Mitchell JB, Krishna MC.

Magn Reson Med. 2012 Mar;67(3):801-7. doi: 10.1002/mrm.23065. Epub 2011 Oct 17.

3.

Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia.

Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, Gadisetti C, Subramanian S, Devasahayam N, Munasinghe JP, Mitchell JB, Krishna MC.

Cancer Res. 2011 Oct 15;71(20):6350-9. doi: 10.1158/0008-5472.CAN-11-2025. Epub 2011 Aug 30.

4.

Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents.

Zhang Q, Bindokas V, Shen J, Fan H, Hoffman RM, Xing HR.

Mol Cancer Ther. 2011 Jul;10(7):1173-84. doi: 10.1158/1535-7163.MCT-11-0008. Epub 2011 May 17.

5.

Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice.

Yasui H, Matsumoto S, Devasahayam N, Munasinghe JP, Choudhuri R, Saito K, Subramanian S, Mitchell JB, Krishna MC.

Cancer Res. 2010 Aug 15;70(16):6427-36. doi: 10.1158/0008-5472.CAN-10-1350. Epub 2010 Jul 20.

6.

Estimation of tumor microvessel density by MRI using a blood pool contrast agent.

Hyodo F, Chandramouli GV, Matsumoto S, Matsumoto K, Mitchell JB, Krishna MC, Munasinghe JP.

Int J Oncol. 2009 Oct;35(4):797-804.

PMID:
19724915
7.

Reconstruction for time-domain in vivo EPR 3D multigradient oximetric imaging--a parallel processing perspective.

Dharmaraj CD, Thadikonda K, Fletcher AR, Doan PN, Devasahayam N, Matsumoto S, Johnson CA, Cook JA, Mitchell JB, Subramanian S, Krishna MC.

Int J Biomed Imaging. 2009;2009:528639. doi: 10.1155/2009/528639. Epub 2009 Aug 5.

8.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.

9.

Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.

Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, Hamstra DA.

Clin Cancer Res. 2009 Jan 15;15(2):589-96. doi: 10.1158/1078-0432.CCR-08-1019.

10.

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.

Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, Maira SM.

Cancer Res. 2008 Aug 15;68(16):6598-607. doi: 10.1158/0008-5472.CAN-08-1044.

11.

Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice.

Matsumoto S, Hyodo F, Subramanian S, Devasahayam N, Munasinghe J, Hyodo E, Gadisetti C, Cook JA, Mitchell JB, Krishna MC.

J Clin Invest. 2008 May;118(5):1965-73. doi: 10.1172/JCI34928.

12.

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.

Zhou Q, Guo P, Gallo JM.

Clin Cancer Res. 2008 Mar 1;14(5):1540-9. doi: 10.1158/1078-0432.CCR-07-4544. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308-9.

13.

A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.

Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, Gutkind JS.

Cancer Res. 2008 Feb 15;68(4):1144-53. doi: 10.1158/0008-5472.CAN-07-1756.

14.

Mammalian target of rapamycin as a therapeutic target in oncology.

Abraham RT, Eng CH.

Expert Opin Ther Targets. 2008 Feb;12(2):209-22. doi: 10.1517/14728222.12.2.209 . Review.

PMID:
18208369
15.

Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.

Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses García A, Raimondi AR, Jufe R, Itoiz M, Gao Y, Saranath D, Kaleebi GS, Yoo GH, Leak L, Myers EM, Shintani S, Wong D, Massey HD, Yeudall WA, Lonardo F, Ensley J, Gutkind JS.

Clin Cancer Res. 2007 Sep 1;13(17):4964-73.

16.

Defining the role of mTOR in cancer.

Guertin DA, Sabatini DM.

Cancer Cell. 2007 Jul;12(1):9-22. Review.

17.

Strategies for improved temporal and spectral resolution in in vivo oximetric imaging using time-domain EPR.

Devasahayam N, Subramanian S, Murugesan R, Hyodo F, Matsumoto K, Mitchell JB, Krishna MC.

Magn Reson Med. 2007 Apr;57(4):776-83.

18.

Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.

Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ, Lu B.

Cancer Res. 2006 Oct 15;66(20):10040-7.

19.

mTOR and cancer therapy.

Easton JB, Houghton PJ.

Oncogene. 2006 Oct 16;25(48):6436-46. Review.

PMID:
17041628
20.

Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.

Muruganandham M, Lupu M, Dyke JP, Matei C, Linn M, Packman K, Kolinsky K, Higgins B, Koutcher JA.

Mol Cancer Ther. 2006 Aug;5(8):1950-7.

Supplemental Content

Support Center